Overview
- Editors:
-
-
Saïd M. Sebti
-
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA
-
Andrew D. Hamilton
-
Department of Chemistry, Yale University, New Haven, USA
Access this book
Other ways to access
Table of contents (17 chapters)
-
-
-
- Chih-Chin Huang, Carol A. Fierke, Patrick J. Casey
Pages 21-36
-
- Stephen B. Long, Lorena S. Beese
Pages 37-48
-
- David Knowles, Jiazhi Sun, Saul Rosenberg, Saïd M. Sebti, Andrew D. Hamilton
Pages 49-64
-
- Jackson B. Gibbs, Samuel L. Graham, George D. Hartman, Kenneth S. Koblan, Nancy E. Kohl, Charles Omer et al.
Pages 65-70
-
- Veeraswamy Manne, Frank Lee, Ning Yan, Craig Fairchild, William C. Rose
Pages 71-86
-
- W. Robert Bishop, James J.-K. Pai, Lydia Armstrong, Marguerite B. Dalton, Ronald J. Doll, Arthur Taveras et al.
Pages 87-101
-
- Judith S. Sebolt-Leopold, Daniele M. Leonard, W. R. Leopold
Pages 103-114
-
- Patrick Mailliet, Abdel Laoui, Jean-Dominique Bourzat, Marc Capet, Michel Chevé, Alain Commerçon et al.
Pages 115-144
-
- Fuyuhiko Tamanoi, Keith Del Villar, Nicole Robinson, MeeRhan Kim, Jun Urano, Wenli Yang
Pages 145-157
-
-
- Eric J. Bernhard, Ruth J. Muschel, Elizabeth Cohen-Jonathan, Gilles Favre, Andrew D. Hamilton, Saïd M. Sebti et al.
Pages 171-195
-
- Saïd M. Sebti, Andrew D. Hamilton
Pages 197-219
-
- Michael H. Gelb, Frederick S. Buckner, Kohei Yokoyama, Junko Ohkanda, Andrew D. Hamilton, Lisa Nguyen et al.
Pages 221-232
-
- Amita Patnaik, Eric K. Rowinsky
Pages 233-249
-
- Gary R. Hudes, Jessie Schol
Pages 251-254
-
- Adrienne D. Cox, L. Gerard Toussaint III, James J. Fiordalisi, Kelley Rogers-Graham, Channing J. Der
Pages 255-273
-
Back Matter
Pages 275-280
About this book
With the explosion of research on genes capable of causing cancer, it has become clear that mutations in the GTPase, Ras, a major regulator of cell division, are found in about 30% of all human cancers, and that farnesylation, a lipid posttranslational modification of Ras, is required for its cancer-causing activity. In Farnesyltransferase Inhibitors in Cancer Therapy, cutting-edge researchers describe their efforts to design, synthesize, and evaluate the biological activities of farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase inhibitors (GGTIs) that can be used as anticancer drugs and in cardiovascular and parasitic therapy. The authors survey in detail such inhibitors as CAAX box peptidomimetics, FPP mimics, and bisubstrate transition state analogs, and critically review their uses in combination with radiation and other cytotoxic agents, such as gemcitabine, cisplatin, and taxanes. The book also discusses the results from several phase I and II human clinical trials using a variety of FTIs, and demonstrates the design of hypothesis-driven clinical trials with proof-of-concept using biochemical endpoints.
Illuminating and richly detailed, Farnesyltransferase Inhibitors in Cancer Therapy constitutes today's standard reference for the pathbreaking use of FTIs and GGTIs in anticancer therapy and offers basic and clinical investigators a comprehensive treatment of the scientific and medical aspects of farnesyltransferase inhibitors.
Editors and Affiliations
-
H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA
Saïd M. Sebti
-
Department of Chemistry, Yale University, New Haven, USA
Andrew D. Hamilton
